Compare SBLK & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBLK | SUPN |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2007 | 2010 |
| Metric | SBLK | SUPN |
|---|---|---|
| Price | $27.33 | $50.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $25.50 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 910.6K | 632.7K |
| Earning Date | 05-20-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $11.56 | $22.70 |
| Revenue Next Year | N/A | $19.14 |
| P/E Ratio | $47.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.78 | $31.16 |
| 52 Week High | $27.25 | $59.68 |
| Indicator | SBLK | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 74.32 | 50.83 |
| Support Level | $18.09 | $47.85 |
| Resistance Level | N/A | $52.26 |
| Average True Range (ATR) | 0.66 | 2.15 |
| MACD | 0.20 | 0.19 |
| Stochastic Oscillator | 100.00 | 56.16 |
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. The firm generates the majority of its revenue from Time charters and Voyage charters.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.